Carefusion buys Medegen for $225M

CareFusion is buying Medegen, a maker of clinically differentiated needleless access valves and administration sets that deliver intravenous medication to patients, for $225 million in cash. According to CareFusion, the two companies have complementary product lines that combine will improve delivery of IV medications. "Medegen is an ideal strategic fit with CareFusion due to the complementary nature of our infusion product lines, R&D investments, and our focus on products that are backed by clinical evidence and differentiation," says David Schlotterbeck, chairman and CEO of CareFusion. CareFusion release

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.